Key result
Mesenchymal stem cell-derived LPL reduces hepatic lipid accumulation in preclinical MASLD via LRP1-mediated lipid oxidation.
Why the study?
Mesenchymal stem/stromal cells have the potential to improve hepatic lipid metabolism in metabolic dysfunction-associated steatotic liver disease, but the underlying mechanisms remain unclear.
Does treatment with human umbilical cord mesenchymal stem cells or their conditioned medium ameliorate hepatic lipid accumulation and promote lipid oxidation via the LPL-LRP1 axis in preclinical models of MASLD?
Does treatment with human umbilical cord mesenchymal stem cells or their conditioned medium ameliorate hepatic lipid accumulation and promote lipid oxidation via the LPL-LRP1 axis in preclinical models of MASLD?
This preclinical study identifies the paracrine LPL-LRP1 signaling axis as a key mechanism by which mesenchymal stem cells enhance hepatic lipid oxidation and ameliorate metabolic dysfunction-associated steatotic liver disease (MASLD).
Answers are grounded in this paper and cite their sources.
Should not yet change MASLD practice; hypothesis-generating for LPL-LRP1-targeted therapies in humans.
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disorder characterized primarily by excessive lipid accumulation in liver cells. It affects nearly a quarter of the global population and significantly impairs quality of life. Recent studies shown that mesenchymal stem/stromal cells (MSCs) have the potential to improve hepatic lipid metabolism, offering a novel therapeutic approach for MASLD. However, the mechanisms by which MSCs ameliorate MASLD remain unclear. Method Human hepatocellular carcinoma cells and primary hepatocytes from mice were used to establish a cellular model of MASLD by incubating them with oleic acid and palmitic acid. Additionally, a MASLD mouse model was created using a high-fat diet. The effects of human umbilical cord MSCs on hepatocyte lipid metabolism and the underlying mechanisms were evaluated in vitro using Transwell co-culture systems. The therapeutic efficacy of MSCs in MASLD mice was assessed via tail vein injection. MSC-mediated effects on hepatocyte lipid metabolism were analyzed using Oil Red O staining, RT-qPCR, Western blotting, and immunofluorescence. Results Both MSC co-culture using the Transwell system and supplementation with MSC-conditioned medium effectively ameliorate hepatic lipid droplet accumulation and enhance lipid oxidation in hepatocytes. Additionally, tail vein injection of either MSCs or concentrated MSC-conditioned medium markedly attenuates lipid deposition and hepatic damage in MASLD mice. Mechanistically, MSC-secreted lipoprotein lipase (LPL) was identified as a key regulator of hepatocyte lipid metabolism, promoting lipid oxidation and reducing intrahepatic lipid accumulation through interaction with low-density lipoprotein receptor-related protein 1 (LRP1) on hepatocytes. Conclusion This study identifies the LPL-LRP1 axis as a novel paracrine mechanism driving MSC-mediated amelioration of MASLD. By establishing LPL-dependent engagement of hepatocyte LRP1 as the central functional mechanism for enhancing lipid oxidation and reducing intrahepatic lipid accumulation, these findings provide a mechanistic foundation for targeted therapeutic strategies in MASLD and related metabolic disorders. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied Metabolic dysfunction-associated steatotic liver disease (MASLD). Human umbilical cord-derived mesenchymal stem cells (MSCs) or MSC-conditioned medium (MSC-CM) vs. Untreated high-fat diet MASLD control mice / AAV8-shCtr control was evaluated on Hepatic lipid droplet accumulation, MASLD Activity Score, and hepatic lipid oxidation (p=<0.05). Mesenchymal stem cell-secreted lipoprotein lipase (LPL) binds hepatocyte LRP1 to enhance lipid oxidation and reduce hepatic lipid accumulation in preclinical MASLD models.
Synapse has enriched 10 related papers. Consider them for comparative context: